Earnings Feed
Start Free
Home/Filings/4/0001209191-17-003460
4//SEC Filing

ONCOGENEX PHARMACEUTICALS, INC. 4

Accession 0001209191-17-003460

$ACHVCIK 0000949858operating
View on SEC.govCompany Profile

Filed

Jan 11, 7:00 PM ET

Accepted

Jan 12, 11:31 AM ET

Size

22.7 KB

Accession

0001209191-17-003460

Insider Transaction Report

Form 4
Period: 2017-01-10
ONCOGENEX PHARMACEUTICALS, INC.OGXI
Cormack Scott Daniel
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2017-01-10−6,250→ 6,250 total
    Exp: 2018-04-13→ Common Stock (6,250 underlying)
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2017-01-10−4,687→ 0 total
    Exp: 2017-01-31→ Common Stock (4,687 underlying)
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2017-01-10−9,375→ 18,750 total
    Exp: 2019-06-18→ Common Stock (9,375 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2017-01-10−2,500→ 0 total(indirect: By Spouse)
    Exp: 2017-01-31→ Common Stock (2,500 underlying)
  • Exercise/Conversion

    Common Stock

    2017-01-10+10,312→ 84,055 total(indirect: By Spouse)
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2017-10-10−3,125→ 3,125 total(indirect: By Spouse)
    Exp: 2018-04-13→ Common Stock (3,125 underlying)
  • Exercise/Conversion

    Common Stock

    2017-01-10+20,312→ 149,740 total
  • Tax Payment

    Common Stock

    2017-01-10$0.63/sh−9,690$6,105→ 140,050 total
  • Exercise/Conversion

    Restricted Stock Unit (RSU)

    2017-10-10−4,687→ 9,375 total(indirect: By Spouse)
    Exp: 2019-06-18→ Common Stock (4,687 underlying)
Footnotes (6)
  • [F1]Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
  • [F2]Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
  • [F4]Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.
  • [F5]Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
  • [F6]Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open.

Documents

1 file

Issuer

ONCOGENEX PHARMACEUTICALS, INC.

CIK 0000949858

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000949858

Filing Metadata

Form type
4
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 11:31 AM ET
Size
22.7 KB
View on SEC.gov